Related Experiment Video
Updated: Aug 6, 2025
09:40
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
2.7K
Osteopontin as a Tumor Marker in Ovarian Cancer
Shikha Rani1, Alka Sehgal2, Jasbinder Kaur3
1Department of Obstetrics and Gynaecology, Dr. BR Ambedkar Institute of Medical Sciences, Mohali, Punjab, India.
Journal of Mid-Life Health
|March 23, 2023
Summary
Plasma osteopontin (OPN) shows promise as a biomarker for ovarian cancer, demonstrating higher specificity than CA125 in differentiating malignant from benign ovarian masses. This finding suggests OPN could improve ovarian cancer diagnosis.
Area of Science:
- Gynecologic Oncology
- Biomarker Discovery
- Diagnostic Test Evaluation
Background:
- Ovarian cancer presents significant morbidity and mortality due to nonspecific symptoms and lack of effective screening.
- Current diagnostic marker, carbohydrate antigen-125 (CA125), has limitations.
- There is a critical need for novel biomarkers for early and accurate ovarian cancer detection.
Purpose of the Study:
- To evaluate the diagnostic performance of plasma osteopontin (OPN) for detecting ovarian malignancy.
- To compare the diagnostic accuracy of OPN with the established marker CA125.
Main Methods:
- A prospective cross-sectional study involving 106 women with suspected adnexal masses.
- Measurement of plasma osteopontin (OPN) and carbohydrate antigen-125 (CA125) levels in all participants.
- Analysis of diagnostic test characteristics including sensitivity, specificity, and likelihood ratios.
Main Results:
- Plasma OPN levels were significantly higher in ovarian cancer patients compared to those with benign masses (P=0.001).
- OPN demonstrated a sensitivity of 50% and specificity of 87%, with a positive likelihood ratio of 2.58.
- CA125 showed higher sensitivity (88.5%) but lower specificity (61.3%) compared to OPN.
Conclusions:
- Plasma osteopontin (OPN) exhibits superior specificity compared to CA125 in distinguishing ovarian cancer from benign ovarian masses.
- OPN holds potential as a valuable biomarker for improving the differentiation of benign and malignant ovarian conditions.
- Further research may validate OPN's role in ovarian cancer diagnostics.
